Zhejiang Hisun Pharmaceutical announced that its holding subsidiary, Zhejiang Hisun Animal Health Company, recently received approval numbers issued by the Ministry of Agriculture and Rural Affairs for Amoxicillin and Clavulanate Potassium Dry Suspension and Calofen Injection veterinary drug products. These two products are intended for the treatment of skin and soft tissue infections in dogs and cats, as well as for the relief of pain and inflammation associated with canine osteoarthritis. The approval numbers are valid from November 20, 2024, to November 19, 2029.
海正药业：子公司获两项兽药产品批准文号
Zhejiang Hisun Pharmaceutical: Subsidiary receives approval numbers for two veterinary drug products.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated